Who makes CS1003 monoclonal antibody?

CS1003 monoclonal antibody is developed by CStone Pharmaceuticals.

What development phase is CS1003 monoclonal antibody in?

CS1003 monoclonal antibody is in Phase 1.

Last reviewed 2026-04-19 · How we verify

CS1003 monoclonal antibody

CStone Pharmaceuticals · Phase 1 active Small molecule

At a glance

Generic name	CS1003 monoclonal antibody
Sponsor	CStone Pharmaceuticals
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CS1003 monoclonal antibody CI brief — competitive landscape report
CS1003 monoclonal antibody updates RSS · CI watch RSS
CStone Pharmaceuticals portfolio CI